Abbott Laboratories (ABT) has issued a recall for some of its FreeStyle Libre 3 sensors after discovering that a small number of these devices may provide inaccurate high glucose readings. The use of affected sensors poses a serious health risk, potentially causing severe low blood sugar (hypoglycemia). This condition can lead to a range of complications, including central nervous system problems, loss of consciousness, seizures, coma, permanent brain damage, and even death.
Two cases of injuries related to the faulty sensors have been reported, though no deaths have been linked to the recall. The recall involves the removal of affected devices from circulation, but it does not impact the FreeStyle Libre 3 reader or app.
The FreeStyle Libre 3 Continuous Glucose Monitoring System is designed to provide continuous glucose level monitoring, helping individuals manage diabetes by identifying trends and tracking patterns in their glucose levels. This information allows for adjustments to treatment plans as needed. It is important to note that the system is intended for single-patient use and requires a prescription.
In July, Abbott proactively notified all affected customers of the recall, urging them to discontinue using the affected sensors, dispose of them properly, and request replacements.
In a separate announcement, Abbott also launched Lingo, its first prescription-free continuous glucose monitoring system, available in the U.S. This system includes a biosensor and a mobile app specifically designed for individuals seeking to improve their overall health and wellness. Lingo is based on Abbott’s FreeStyle Libre technology, providing real-time glucose tracking and offering personalized insights and coaching to help users build healthy habits, improve their metabolism, and enhance their overall well-being.
Lingo is available for individuals aged 18 and older who are not currently on insulin.
ABT stock closed down 0.82% at $113.46 on Thursday.
